Table 1.
Trials of Regional Chemotherapy for Pancreatic Cancer: Patient Demographics, Technical Approach, and Chemotherapy
| Author (Year) | Country | Patients | Mean Age1 | Gender (M:F) | Procedure□ | Chemotherapeutic agents |
|---|---|---|---|---|---|---|
| Fiorentini (1996) | Italy | 20 | NR | 16:4 | HAP | MMC |
| Muchmore (1996) | USA | 12 | 56 | 3:9 | CAI | MMC, 5-FU, Folinic acid |
| Link (1997) | Gemany | 32 | 60 | 19:13 | CAI | CDDP, Mitoxantrone, 5-FU, Folinic acid |
| Lorenz (1998) | Germany | 17 | 61* | 12:5 | HAP | MMC |
| Maurer (1998) | Switzerland | 12 | 59.9 | 9:3 | CAI | CDDP, Mitoxantrone, 5-FU, Folinic acid |
| Klapdor (1999) | Germany | 28 | NR | 17:11 | CAI | Gemcitabine, MMC |
| Homma (2000) | Japan | 31 | 61.5 | 18:13 | SAI | CDDP, 5-FU, Folinic acid |
| Bayar (2003) | Turkey | 14 | 55* | 8:6 | CAI | CDDP, MMC, 5-FU, Folinic acid |
| Ohigashi (2003) | Japan | 32 | 60 | 20:12 | SAI | Angiotensin-II, Methotrexate |
| van Ijken (2004) | Netherlands | 21 | 59 | 12:9 | CAI2 / HAP | Melphalan, MMC |
| Aigner (2005) | Germany | 265 | NR | NR | CAI / HAP | CDDP, Mitoxantrone, MMC, degradable startch microspheres |
| Takamori (2005) | Japan | 24 | 62.6* | 16:8 | CAI3 | Gemcitabine, 5-FU, Folinic acid |
| Barletta (2006) | Italy | 32 | 62* | 22:10 | SAI4 | Carboplatin, Epirubicin, 5-FU, Folinic acid |
| Mambrini (2006) | Italy | 211 | 61* | 130:81 | CAI | Carboplatin, Epirubicin, 5-FU, Folinic acid |
| Meyer (2006) | Germany | 17 | 54.5 | 11:6 | HAP | MMC |
| Guadagni (2007) | Italy | 22 | 66* | 12:10 | HAP | CDDP, MMC |
| Ikeda (2007) | Japan | 33 | 60 | 22:11 | SAI5 | Gemcitabine, 5-FU, Folinic acid |
| Ishikawa (2007) | Japan | 20 | 63.7* | 9:11 | CAI | Angiotensin-II, CDDP, Gemcitabine, 5-FU, Folinic acid |
| Milandri (2007) | Italy | 19 | 62* | 12:7 | SAI4 | Carboplatin, Epirubicin, 5-FU, Folinic acid |
| Nakchbandi (2008) | Germany | 17 | 65.7 | 11:6 | CAI | Gemcitabine, MMC, Warfarin |
| Sasada (2008) | Japan | 16 | 61.2 | 10:6 | SAI5 | CDDP, 5-FU, Folinic acid |
□
HAP, hypoxic abdominal perfusion; CAI, celiac axis infusion; SAI, selective arterial infusion; MMC, mitomycin C; 5-FU, 5-fluorouracil; CDDP, cis-platinum;
1
NR, not reported;
*
Studies reporting median age.
2
CAI performed in 9 of 21 patients that underwent HAP.
3
CAI performed after selective peri-pancreatic artery embolization.
4
Patients with liver metastases received half of chemotherapy dose via hepatic artery.
5
SAI preceded by selective arterial embolization.